From recent studies, fibroblast growth factor-21 (FGF-21) and irisin have been known to be peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1 alpha)-related potential therapeutic targets for metabolic diseases. This evidence concerns the gene PPARGC1A and metabolic disease.